Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study

BACKGROUND: Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available in the United Kingdom to adults aged 65 years or older and those in defined clinical risk groups. We evaluated the vaccine effectiveness (VE) of PPV23 against vaccine-type pneumococcal pneumonia in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawrence, Hannah, Pick, Harry, Baskaran, Vadsala, Daniel, Priya, Rodrigo, Chamira, Ashton, Deborah, Edwards-Pritchard, Rochelle C., Sheppard, Carmen, Eletu, Seyi D., Litt, David, Fry, Norman K., Rose, Samuel, Trotter, Caroline, McKeever, Tricia M., Lim, Wei Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584218/
https://www.ncbi.nlm.nih.gov/pubmed/33095759
http://dx.doi.org/10.1371/journal.pmed.1003326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584218/
https://www.ncbi.nlm.nih.gov/pubmed/33095759
http://dx.doi.org/10.1371/journal.pmed.1003326

Ejemplares similares